UTHR Quote, Financials, Valuation and Earnings

Geron has a net margin of 40.94% compared to United Therapeutics's net margin of -53.33%. United Therapeutics's return on equity of 20.21% beat Geron's return on equity of -59.29%.

United Therapeutics has a consensus price target of $392.22, signalling upside risk potential of 27.81%. On the other hand Geron has an analysts' consensus of $4.50 which suggests that it could grow by 204.05%. Given that Geron has higher upside potential than United Therapeutics, analysts believe Geron is more attractive than United Therapeutics.

United Therapeutics has a beta of 0.632, which suggesting that the stock is 36.833% less volatile than S&P 500. In comparison Geron has a beta of 0.661, suggesting its less volatile than the S&P 500 by 33.916%.

United Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Geron offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. United Therapeutics pays -- of its earnings as a dividend. Geron pays out -- of its earnings as a dividend.

United Therapeutics quarterly revenues are $735.9M, which are larger than Geron quarterly revenues of $47.5M. United Therapeutics's net income of $301.3M is higher than Geron's net income of -$25.4M. Notably, United Therapeutics's price-to-earnings ratio is 12.47x while Geron's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for United Therapeutics is 5.18x versus 12.42x for Geron. Usually stocks with elevated PS ratios are considered overvalued.

Madrigal Pharmaceuticals has a net margin of 40.94% compared to United Therapeutics's net margin of -57.51%. United Therapeutics's return on equity of 20.21% beat Madrigal Pharmaceuticals's return on equity of -63.91%.

United Therapeutics has a consensus price target of $392.22, signalling upside risk potential of 27.81%. On the other hand Madrigal Pharmaceuticals has an analysts' consensus of $414.07 which suggests that it could grow by 27.81%. Given that United Therapeutics has higher upside potential than Madrigal Pharmaceuticals, analysts believe United Therapeutics is more attractive than Madrigal Pharmaceuticals.

United Therapeutics has a beta of 0.632, which suggesting that the stock is 36.833% less volatile than S&P 500. In comparison Madrigal Pharmaceuticals has a beta of -0.683, suggesting its less volatile than the S&P 500 by 168.299%.

United Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Madrigal Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. United Therapeutics pays -- of its earnings as a dividend. Madrigal Pharmaceuticals pays out -- of its earnings as a dividend.

United Therapeutics quarterly revenues are $735.9M, which are larger than Madrigal Pharmaceuticals quarterly revenues of $103.3M. United Therapeutics's net income of $301.3M is higher than Madrigal Pharmaceuticals's net income of -$59.4M. Notably, United Therapeutics's price-to-earnings ratio is 12.47x while Madrigal Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for United Therapeutics is 5.18x versus -- for Madrigal Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of 40.94% compared to United Therapeutics's net margin of 2.31%. United Therapeutics's return on equity of 20.21% beat Pfizer's return on equity of 8.91%.

United Therapeutics has a consensus price target of $392.22, signalling upside risk potential of 27.81%. On the other hand Pfizer has an analysts' consensus of $31.26 which suggests that it could grow by 27.38%. Given that United Therapeutics has higher upside potential than Pfizer, analysts believe United Therapeutics is more attractive than Pfizer.

United Therapeutics has a beta of 0.632, which suggesting that the stock is 36.833% less volatile than S&P 500. In comparison Pfizer has a beta of 0.670, suggesting its less volatile than the S&P 500 by 32.954%.

United Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.89% to investors and pays a quarterly dividend of $0.43 per share. United Therapeutics pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

United Therapeutics quarterly revenues are $735.9M, which are smaller than Pfizer quarterly revenues of $17.8B. United Therapeutics's net income of $301.3M is lower than Pfizer's net income of $410M. Notably, United Therapeutics's price-to-earnings ratio is 12.47x while Pfizer's PE ratio is 17.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for United Therapeutics is 5.18x versus 2.20x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Zoetis has a net margin of 40.94% compared to United Therapeutics's net margin of 25.08%. United Therapeutics's return on equity of 20.21% beat Zoetis's return on equity of 49.71%.

United Therapeutics has a consensus price target of $392.22, signalling upside risk potential of 27.81%. On the other hand Zoetis has an analysts' consensus of $199.99 which suggests that it could grow by 23.52%. Given that United Therapeutics has higher upside potential than Zoetis, analysts believe United Therapeutics is more attractive than Zoetis.

United Therapeutics has a beta of 0.632, which suggesting that the stock is 36.833% less volatile than S&P 500. In comparison Zoetis has a beta of 0.925, suggesting its less volatile than the S&P 500 by 7.51%.

United Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zoetis offers a yield of 1.11% to investors and pays a quarterly dividend of $0.50 per share. United Therapeutics pays -- of its earnings as a dividend. Zoetis pays out 31.62% of its earnings as a dividend. Zoetis's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

United Therapeutics quarterly revenues are $735.9M, which are smaller than Zoetis quarterly revenues of $2.3B. United Therapeutics's net income of $301.3M is lower than Zoetis's net income of $581M. Notably, United Therapeutics's price-to-earnings ratio is 12.47x while Zoetis's PE ratio is 29.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for United Therapeutics is 5.18x versus 7.96x for Zoetis. Usually stocks with elevated PS ratios are considered overvalued.